| Bioactivity | SR12418 is a REV-ERB-specific synthetic ligand with IC50s of 68 nM and 119 nM for REV-ERBα and REV-ERBβ, respectively. SR12418 can be used in experimental autoimmune encephalomyelitis (EAE) and colitis research[1][2]. |
| Target | IC50: 68 nM (REV-ERBα) and 119 nM (REV-ERBβ) |
| Invitro | SR12418 (5 μM; 96 h) inhibits the growth of TH17 cells[1].SR12418 (5 and 10 μM; 4 d) inhibits cell differentiation under TH17 polarizing conditions[1]. RT-PCR[1] Cell Line: |
| In Vivo | SR12418 (intraperitoneal injection; 50 mg/kg; twice a day) suppresses the development and severity of experimental autoimmune encephalomyelitis[1].SR12418 (intraperitoneal injection; 50 mg/kg; twice a day; begin at day 18 post-immunization) shows effects in intervention studies of relapsing-remitting experimental autoimmune encephalomyelitis[1]. Animal Model: |
| Name | SR12418 |
| CAS | 1801185-08-9 |
| Formula | C31H30FNO3 |
| Molar Mass | 483.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mohammed Amir, et al. REV-ERBα Regulates TH17 Cell Development and Autoimmunity. Cell Rep. 2018 Dec 26;25(13):3733-3749.e8. [2]. Shuai Wang, et al. Targeting REV-ERBα for therapeutic purposes: promises and challenges. Theranostics. 2020 Mar 4;10(9):4168-4182. |